GCM
KLRS

Graham Capital Management’s Kalaris Therapeutics KLRS Stock Holding History

Graham Capital Management’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-3,576
Closed -$55.9K – 1347
2023
Q4 		$55.9K Buy
3,576
+3,056
+588% +$121K ﹤0.01% 937
2023
Q3 		$25.7K Buy
+520
New +$35.4K ﹤0.01% 978
2022
Q4 		– Sell
-562
Closed -$102K – 1401
2022
Q3 		$102K Buy
+562
New +$87.6K ﹤0.01% 1024

Other funds holding KLRS

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ICM
Irenic Capital Management New York $1.54B AUM 12.79% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Graham Capital Management's KLRS Position: Q1 2024 in Review

Graham Capital Management sold out of Kalaris Therapeutics (KLRS) in Q1 2024, closing a stake of 3,576 shares — an estimated $55.9K sold.

Graham Capital Management first reported a position in KLRS in Q3 2022 and held it in 3 quarters. The position peaked at $102K in Q3 2022. 76 funds tracked by Wall St. Rank hold KLRS as of Q1 2024.

  • Graham Capital Management reported no remaining Kalaris Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Graham Capital Management sold 3,576 Kalaris Therapeutics shares in Q1 2024, an estimated $55.9K.
  • Graham Capital Management first reported a position in Kalaris Therapeutics in Q3 2022 and held it in 3 quarters.
  • Graham Capital Management's Kalaris Therapeutics position peaked at $102K in Q3 2022.
  • 76 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q1 2024.

Based on Graham Capital Management's 13F filing for Q1 2024, filed 15 May 2024.